PATIENT EDUCATION MATERIALS to help introduce your patients to JUBLIA

Important information to share with your patients

For patients just starting on JUBLIA, here is some useful information to share when they are in your office1:

  • JUBLIA is a prescription medicine used on the skin and nail (topical) to treat toenail fungus in people 18 years of age and older. It is not known if JUBLIA is safe and effective in children
  • JUBLIA should be applied to affected toenails 1 time each day for 48 weeks
  • Wait for at least 10 minutes after showering, bathing, or washing before applying
Useful patient information sheet

Helpful Patient Brochure

This brochure contains information on onychomycosis, risk factors, and how JUBLIA works.

Download

Useful patient information sheet

Useful Patient Information Sheet

This document provides patients with information on onychomycosis and on how to use JUBLIA properly to get the most out of their treatment. Give one of these to your patients any time you prescribe JUBLIA.

Download

Healthy Rewards Program

Healthy Rewards Program: JUBLIA PointsTM

Patients with a prescription for JUBLIA can sign up to join the JUBLIA PointsTM Program at JUBLIAPoints.com. Participants can track their prescription, engage and earn healthy rewards daily, and redeem their rewards for great health prizes.

Learn More

Indication

JUBLIA (efinaconazole) topical solution, 10% is indicated for the topical treatment of onychomycosis (tinea unguium) of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Important Safety Information

  • JUBLIA is for topical use only and is not for oral, ophthalmic, or intravaginal use.
  • Patients should be instructed to contact their health care professional if a reaction suggesting sensitivity or severe irritation occurs.
  • The most common adverse reactions (incidence >1%) were (vs vehicle): ingrown toenail (2.3% vs 0.7%), application-site dermatitis (2.2% vs 0.2%), application-site vesicles (1.6% vs 0%), and application-site pain (1.1% vs 0.2%).
  • JUBLIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and should be used with caution in nursing women. The safety and effectiveness in pediatric patients have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see JUBLIA Prescribing Information.

Reference: 1. JUBLIA [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2016.

INDICATION

JUBLIA (efinaconazole) topical solution, 10% is indicated for the topical treatment of onychomycosis (tinea unguium) of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Please see JUBLIA Prescribing Information.

IMPORTANT SAFETY INFORMATION

  • JUBLIA is for topical use only and is not for oral, ophthalmic, or intravaginal use.
  • Patients should be instructed to contact their health care professional if a reaction suggesting sensitivity or severe irritation occurs.
  • The most common adverse reactions (incidence >1%) were (vs vehicle): ingrown toenail (2.3% vs 0.7%), application-site dermatitis (2.2% vs 0.2%), application-site vesicles (1.6% vs 0%), and application-site pain (1.1% vs 0.2%).
  • JUBLIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and should be used with caution in nursing women. The safety and effectiveness in pediatric patients have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.